10.70
Roivant Sciences Ltd stock is traded at $10.70, with a volume of 2.04M.
It is up +1.23% in the last 24 hours and down -4.13% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$10.56
Open:
$10.56
24h Volume:
2.04M
Relative Volume:
0.44
Market Cap:
$7.54B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
1.8944
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
+1.91%
1M Performance:
-4.13%
6M Performance:
-4.47%
1Y Performance:
-7.77%
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
Compare ROIV with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ROIV
Roivant Sciences Ltd
|
10.69 | 7.54B | 125.68M | 4.81B | -781.21M | 5.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.97 | 117.87B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
678.60 | 73.64B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
642.01 | 38.85B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
250.66 | 33.20B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
121.81 | 28.73B | 3.30B | -501.07M | 1.03B | -2.1146 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-15-24 | Initiated | Wolfe Research | Outperform |
Jan-05-24 | Initiated | Piper Sandler | Overweight |
Dec-12-23 | Initiated | Deutsche Bank | Buy |
Oct-17-23 | Initiated | Guggenheim | Buy |
Jun-08-23 | Initiated | BofA Securities | Neutral |
Oct-27-22 | Initiated | JP Morgan | Overweight |
May-23-22 | Initiated | SVB Leerink | Outperform |
Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
Dec-15-21 | Initiated | Goldman | Buy |
Nov-08-21 | Initiated | H.C. Wainwright | Buy |
Oct-28-21 | Initiated | Citigroup | Buy |
Oct-26-21 | Initiated | Cowen | Outperform |
Oct-26-21 | Initiated | Jefferies | Buy |
Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 218,041 Shares - MarketBeat
Roivant Sciences president Eric Venker sells over $4.56 million in stock - MSN
Roivant Sciences president Eric Venker sells over $4.56 million in stock By Investing.com - Investing.com South Africa
Roivant Sciences (NASDAQ:ROIV) Shares Gap Up After Earnings Beat - MarketBeat
178,853 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Acquired by Elevate Capital Advisors LLC - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Roivant Sciences: Earnings Reveal Strategic Clinical Advances - MSN
Roivant Sciences targets brepocitinib expansion with new cutaneous sarcoidosis trial amid $5.2B cash position - MSN
Roivant Sciences price target lowered to $12 from $13 at BofA - Yahoo Finance
Roivant Sciences Ltd. (ROIV): A Cheap Biotech Stock to Invest In Now - Yahoo Finance
Roivant Sciences Insiders Sold US$52m Of Shares Suggesting Hesitancy - Simply Wall St
News Flash: Analysts Just Made A Captivating Upgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) Forecasts - Yahoo Finance
Industry Analysts Just Upgraded Their Roivant Sciences Ltd. (NASDAQ:ROIV) Revenue Forecasts By 21% - Simply Wall St
10 Cheap Biotech Stocks to Invest in Now - Insider Monkey
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2024 Earnings Call Transcript - Insider Monkey
Roivant Sciences Tops Q3 Expectations - Mitrade
Roivant Sciences Ltd (ROIV) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial ... By GuruFocus - Investing.com Canada
Roivant Sciences: Strong Earnings Call Amid Challenges - TipRanks
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Tops Revenue Estimates - MSN
Roivant Sciences Ltd. (ROIV) reports earnings - Quartz
Roivant Sciences earnings beat by $0.48, revenue topped estimates - Investing.com Australia
Roivant Sciences Ltd. (ROIV) Tops Q3 EPS by 48c - StreetInsider.com
Roivant Reports Financial Results for Q3 2024 - TradingView
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update - The Manila Times
Roivant Sciences Fiscal Q3 Earnings, Revenue Fall -February 10, 2025 at 07:17 am EST - Marketscreener.com
Roivant Sciences Q3 Earnings Assessment - Benzinga
Earnings Flash (ROIV) Roivant Sciences Posts Q3 Revenue $9M, vs. FactSet Est of $5M - Marketscreener.com
Roivant's $5.2B War Chest Fuels Ambitious Clinical Pipeline as Loss Widens in Q3 - StockTitan
Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by DAVENPORT & Co LLC - MarketBeat
Trading (ROIV) With Integrated Risk Controls - Stock Traders Daily
Roivant Sciences (ROIV) to Release Quarterly Earnings on Monday - Defense World
What To Expect From Roivant Sciences Ltd (ROIV) Q3 2025 Earnings - Yahoo Finance
Roivant Sciences (ROIV) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Bought by KBC Group NV - Defense World
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade) - Seeking Alpha
Roivant Sciences (NASDAQ:ROIV) Rating Increased to Strong-Buy at Cantor Fitzgerald - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Upgraded at Cantor Fitzgerald - Defense World
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Trump Index: 6 Companies Linked to Trump’s Cabinet Worth Watching - MarketBeat
Trump Index: 6 Companies Linked to Trump's Cabinet Worth Watching - Benzinga
Roivant sciences president Eric Venker sells $1.13 million in shares - MSN
Zweig DiMenna Associates LLC Takes Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Roivant Sciences Ltd Stock (ROIV) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Venker Eric | President & COO |
Feb 13 '25 |
Option Exercise |
3.85 |
300,000 |
1,155,000 |
1,114,910 |
Venker Eric | President & COO |
Feb 12 '25 |
Sale |
10.53 |
217,384 |
2,289,054 |
732,294 |
Venker Eric | President & COO |
Feb 13 '25 |
Sale |
10.42 |
218,041 |
2,271,987 |
896,869 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):